Vantrexa · NSCLC · Germany · Pathologist · captured by James Whitfield on 17 Jan 2026 · reviewed by Dr. Sophie Laurent on 21 Jan 2026
Verbatim as captured; never edited
Pathologist at Universitätsklinikum Heidelberg raised sequencing after progression during a payer / hta meeting. They asked whether additional data would be presented at the next congress.
Human-approved by Dr. Sophie Laurent on 21 Jan 2026
Sequencing after progression: gap in current materials reported by pathologist (DE).
helixor-private-llm-2026.05 · generated 17 Jan 2026, 10:00 UTC
AI summary
Sequencing after progression raised by pathologist; relevant for Medical Communications.
Source spans used by the model
Pathologist at Universitätsklinikum Heidelberg raised sequencing after progression during a payer / hta meeting. They asked whether additional data would be presented at the next congress.
| Field | AI suggestion | Final (human-approved) |
|---|---|---|
| Category | Competitor activity | Competitor activity |
| Function | Medical Communications | Medical Communications |
| Priority | High | High |
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 4 | 20% | 16.0 |
| Strategic alignment | 4 | 20% | 16.0 |
| Scientific importance | 2 | 15% | 6.0 |
| Urgency | 3 | 15% | 9.0 |
| Novelty | 5 | 10% | 10.0 |
| Actionability | 3 | 10% | 6.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 1 | 5% | 1.0 |
| Total | High 69 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
16 Jan 2026 · Dr. Chloé Rossi, Universitätsklinikum Heidelberg · MSL James Whitfield
Insight
Reviewed 21 Jan 2026 by Dr. Sophie Laurent
Action
Medical education program · Dr. Anna Becker · In progress
Decision
Outcome
Closure
Incorporated into evidence-generation plan.